Trials / Conditions / Grade 3a Follicular Lymphoma

Grade 3a Follicular Lymphoma

21 registered clinical trials studyying Grade 3a Follicular Lymphoma — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROM NCT06948786	University of Washington	Phase 2
Recruiting	Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma NCT06442475	University of Washington	Phase 2
Recruiting	Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphom NCT06471738	Chinese PLA General Hospital	Phase 2
Completed	Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-C NCT05169658	University of Washington	Phase 2
Recruiting	Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent NCT04883437	Emory University	Phase 2
Active Not Recruiting	Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymph NCT04450173	University of California, Davis	Phase 2
Active Not Recruiting	Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma NCT04257578	University of Washington	Phase 1 / Phase 2
Active Not Recruiting	Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicu NCT04404088	M.D. Anderson Cancer Center	Phase 2
Completed	TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade NCT03410901	Ronald Levy	Phase 1
Active Not Recruiting	Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas NCT03198026	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	Phase 2
Active Not Recruiting	Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With R NCT03269669	National Cancer Institute (NCI)	Phase 2
Completed	Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocy NCT03010358	Alexey Danilov, MD	Phase 1 / Phase 2
Active Not Recruiting	Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin NCT02992522	Beth Christian	Phase 1
Active Not Recruiting	Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma NCT03015896	David Bond, MD	Phase 1 / Phase 2
Completed	Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma NCT02950220	Kami Maddocks	Phase 1
Completed	Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular NCT02871219	M.D. Anderson Cancer Center	Phase 2
Completed	TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1 NCT02927964	Robert Lowsky	Phase 1 / Phase 2
Completed	Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage NCT02532257	M.D. Anderson Cancer Center	Phase 2
Completed	Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma NCT01995669	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Active Not Recruiting	Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma NCT01849263	National Cancer Institute (NCI)	Phase 2
Completed	Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Folli NCT01286272	National Cancer Institute (NCI)	Phase 2